Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes
- PMID: 179712
Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes
Abstract
The hypothesis that selective action of cyclophosphamide, compared to other nitrogen mustards, is due to a balance between enzymatic formation of inactive metabolites and chemical formation of the alkylating product was studied in view of previous observation in our laboratory. Metabolite analysis, inhibition of growth of tumor cells in culture, and kinetic analysis of relevant enzyme activities were used in this investigation. The effect of tissue-soluble enzyme fractions on biochemically prepared aldophosphamide, aldophosphamide analogs, and phosphoramide mustard showed: (a) a range of deactivation abilities with aldophosphamide (liver greater than kidney greater than intestinal mucosa greater than tumor greater than spleen = bovine serum albumin solution); (b) the formation of different amounts of carboxyphosphamide from aldophosphamide; and (c) only comparatively small reductions in the toxicity of phosphoramide mustard and of 4-hydroxy-4methylcyclophosphamide. Correlations were found between NAD+-dependent aldehyde dehydrogenase activity and the deactivation ability of tissue-soluble enzyme fractions. Blockage (by C4 substitution) or inhibition (by disulfiram) of secondary oxidation of aldophosphamide, mediated by aldehyde dehydrogenase, resulted in diminished deactivation ability in vitro and reduced selectivity in vivo.
Similar articles
-
The enzymatic basis of the selective action of cyclophosphamide.Cancer Res. 1975 Dec;35(12):3755-61. Cancer Res. 1975. PMID: 172233
-
Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.Cancer Treat Rep. 1976 Apr;60(4):337-46. Cancer Treat Rep. 1976. PMID: 1277209
-
Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.Cancer Treat Rep. 1976 Apr;60(4):301-8. Cancer Treat Rep. 1976. PMID: 1277205
-
The chemistry of the metabolites of cyclophosphamide.Curr Pharm Des. 1999 Aug;5(8):627-43. Curr Pharm Des. 1999. PMID: 10469895 Review.
-
Design of new oxazaphosphorine anticancer drugs.Curr Pharm Des. 2007;13(9):963-78. doi: 10.2174/138161207780414296. Curr Pharm Des. 2007. PMID: 17430192 Review.
Cited by
-
Why Great Mitotic Inhibitors Make Poor Cancer Drugs.Trends Cancer. 2020 Nov;6(11):924-941. doi: 10.1016/j.trecan.2020.05.010. Epub 2020 Jun 11. Trends Cancer. 2020. PMID: 32536592 Free PMC article. Review.
-
Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.Cancer Chemother Pharmacol. 1984;12(3):167-72. doi: 10.1007/BF00256539. Cancer Chemother Pharmacol. 1984. PMID: 6705134
-
[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].J Cancer Res Clin Oncol. 1980 Jan;96(1):79-92. doi: 10.1007/BF00412899. J Cancer Res Clin Oncol. 1980. PMID: 7358774 Free PMC article. German.
-
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.J Cancer Res Clin Oncol. 1986;111(1):1-12. doi: 10.1007/BF00402768. J Cancer Res Clin Oncol. 1986. PMID: 3949846 Free PMC article.
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous